drugset / Trial / NCT07079579

Enarodustat Tablets at Different Initial Doses for Anemia in Non-dialysis CKD Patients

NCT07079579

Phase 4 Not yet recruiting 120 enrolled Shenzhen Salubris Pharmaceuticals Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the rationality of different initial doses of enarodustat for the treatment of anemia in ND-CKD patients

Timeline

Start
2025-08
Primary completion
2027-06
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Enarodustat Small molecule 2 mg
Subject Enarodustat Small molecule 3 mg
Subject Enarodustat Small molecule 4 mg

Indications